Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02017249 · ClinicalTrials.gov registry record · Phase 1
Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme
A Phase 1 study, sponsored by Inova Health Care Services.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT02017249 is a Phase 1 study that has completed, run by Inova Health Care Services. The registered enrollment target is 1 participants.
The verdict
NCT02017249, a Phase 1 study, has completed, sponsored by Inova Health Care Services.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to learn more about the ability of a substance called arginine to improve the functioning of the immune system in people with a certain type of brain tumor. This could lead to improvements in a type of treatment for brain tumors called immunotherapy. The immune system includes organs, cells, and substances in the body that fight infection and disease. Immunotherapy is a type of treatment that uses the immune system as a tool to seek out and destroy abnormal cells. Immunotherapy requires that the immune system be working properly. Arginine is a normal component of protein (an amino acid) that we all consume in foods such as red meat, poultry, fish, and dairy products and that our bodies can make. Arginine helps the immune system function normally. Recent research has shown that certain types of brain tumors decrease the amount of arginine in the body leading to impaired immune system function. This may interfere with the ability of immunotherapy to fight abnormal cells. We would like to see if giving people with brain tumors arginine in powder form will make their immune systems work better.
Interventions
- DRUG arginine in powder form
- DRUG Silica and cellulose placebo powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-10-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02017249
The ClinicalTrials.gov registry entry for NCT02017249 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inova Health Care Services, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which arginine in powder form is the first listed.
NCT02017249 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02017249 about?
NCT02017249 is a clinical study titled "Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme". The purpose of this study is to learn more about the ability of a substance called arginine to improve the functioning of the immune system in people with a certain type of brain tumor. This could lead to improvements in a type of treatment for brain tumors called immunotherapy. The immune system in...
What is the current status of trial NCT02017249?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2014-03. Estimated completion is 2015-10-06.
What interventions are being tested in trial NCT02017249?
The interventions under investigation include: arginine in powder form (DRUG), Silica and cellulose placebo powder (DRUG).
Who is sponsoring clinical trial NCT02017249?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.